Donna Clark on the Transition From Oncology Nurse to Patient

Commentary
Video
Conferences|ONS Annual Congress

Donna Clark, RN, Mitchell Cancer Institute, discusses what it was like to be a patient with endometrial cancer after more than two decades of being an oncology nurse.

Donna Clark, RN, Mitchell Cancer Institute, discusses what it was like to be a patient with endometrial cancer after more than two decades of being an oncology nurse.

As an oncology nurse, Clark knew the symptoms, such as fever and infection, to look out for as a patient. Also, by crossing into the patient realm, Clark, who is in remission and back to nursing, now has a better understanding of patients and their side effects, such as fatigue and bone pain since she is “one in the club.”

Related Videos
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, in an interview with Oncology Nursing News
Andrea Wagner, M.S.N., RN, OCN, in an interview with Oncology Nursing News discussing her abstract on verbal orders for CRS.
John Rodriguez in an interview with Oncology Nursing News discussing his abstract on reducing nurse burnout
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Alyssa Ridad
Yelena Shames
Related Content
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer

Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer

May 10th 2024
Article

Patients with high-risk prostate cancer treated with apalutamide with androgen deprivation therapy following radical prostatectomy had a recurrence-free survival rate of 100% after 2 years.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer

TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer

May 9th 2024
Article

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.

The Vitals

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

June 1st 2023
Podcast

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention

Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention

May 8th 2024
Article

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

Nurse Navigators Aid in Timely and Comprehensive Lymphedema Care

Nurse Navigators Aid in Timely and Comprehensive Lymphedema Care

May 2nd 2024
Article

The implementation of a nurse navigator in a lymphedema program has helped patients with the condition obtain timely care, which can potentially improve outcomes.

© 2024 MJH Life Sciences

All rights reserved.